Literature DB >> 17724472

Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis.

D I Lin1, M D Lessie, A B Gladden, C H Bassing, K U Wagner, J A Diehl.   

Abstract

Cyclin D1 levels are maintained at steady state by phosphorylation-dependent nuclear export and polyubiquitination by SCF(FBX4-alphaB crystallin). Inhibition of cyclin D1 proteolysis has been implicated as a causative factor leading to its overexpression in breast and esophageal carcinomas; however, the contribution of stable cyclin D1 to the genesis of such carcinomas has not been evaluated. We therefore generated transgenic mice wherein expression of either wild-type or a stable cyclin D1 allele (D1T286A) is regulated by MMTV-LTR. MMTV-D1T286A mice developed mammary adenocarcinomas at an increased rate relative to MMTV-D1 mice. Similar to human cancers that overexpress cyclin D1, D1T286A tumors were estrogen receptor-positive and exhibited estrogen-dependent growth. Collectively, these results suggest that temporal control of cyclin D1 subcellular localization and proteolysis is critical for maintenance of homeostasis within the mammary epithelium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724472      PMCID: PMC3733559          DOI: 10.1038/sj.onc.1210738

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

Authors:  D W Fry; D C Bedford; P H Harvey; A Fritsch; P R Keller; Z Wu; E Dobrusin; W R Leopold; A Fattaey; M D Garrett
Journal:  J Biol Chem       Date:  2001-02-06       Impact factor: 5.157

2.  The human licensing factor for DNA replication Cdt1 accumulates in G1 and is destabilized after initiation of S-phase.

Authors:  H Nishitani; S Taraviras; Z Lygerou; T Nishimoto
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

Review 3.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.

Authors:  R D Cardiff; M R Anver; B A Gusterson; L Hennighausen; R A Jensen; M J Merino; S Rehm; J Russo; F A Tavassoli; L M Wakefield; J M Ward; J E Green
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

4.  Specific protection against breast cancers by cyclin D1 ablation.

Authors:  Q Yu; Y Geng; P Sicinski
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

5.  Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.

Authors:  J R Alt; J L Cleveland; M Hannink; J A Diehl
Journal:  Genes Dev       Date:  2000-12-15       Impact factor: 11.361

6.  A p53-dependent checkpoint pathway prevents rereplication.

Authors:  Cyrus Vaziri; Sandeep Saxena; Yesu Jeon; Charles Lee; Kazutaka Murata; Yuichi Machida; Nikhil Wagle; Deog Su Hwang; Anindya Dutta
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

7.  Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.

Authors:  Douglas I Lin; Olena Barbash; K G Suresh Kumar; Jason D Weber; J Wade Harper; Andres J P Klein-Szanto; Anil Rustgi; Serge Y Fuchs; J Alan Diehl
Journal:  Mol Cell       Date:  2006-11-03       Impact factor: 17.970

8.  Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.

Authors:  Craig H Bassing; Heikyung Suh; David O Ferguson; Katrin F Chua; John Manis; Mark Eckersdorff; Megan Gleason; Rodrick Bronson; Charles Lee; Frederick W Alt
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

9.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Authors:  David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

10.  Cyclin D1 gene (CCND1) mutations in endometrial cancer.

Authors:  Gema Moreno-Bueno; Sandra Rodríguez-Perales; Carolina Sánchez-Estévez; David Hardisson; David Sarrió; Jaime Prat; Juan C Cigudosa; Xavier Matias-Guiu; José Palacios
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  49 in total

1.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

Review 2.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

3.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

4.  SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination.

Authors:  Mukul K Mittal; Kshipra Singh; Smita Misra; Gautam Chaudhuri
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

5.  Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability.

Authors:  Laura L Pontano; Priya Aggarwal; Olena Barbash; Eric J Brown; Craig H Bassing; J Alan Diehl
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

6.  Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.

Authors:  Lei Zhang; Rong Hu; Yanyong Cheng; Xiaoyang Wu; Siwei Xi; Yu Sun; Hong Jiang
Journal:  Cell Prolif       Date:  2017-07-24       Impact factor: 6.831

7.  Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.

Authors:  Meili Hao; Xiangmei Chen; Ting Zhang; Tao Shen; Qing Xie; Xiujuan Xing; Hongxi Gu; Fengmin Lu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

8.  Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Authors:  Véronique Marsaud; Guergana Tchakarska; Geoffroy Andrieux; Jian-Miao Liu; Doulaye Dembele; Bernard Jost; Joanna Wdzieczak-Bakala; Jack-Michel Renoir; Brigitte Sola
Journal:  Mol Cancer       Date:  2010-05-10       Impact factor: 27.401

9.  PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.

Authors:  E Bobrovnikova-Marjon; C Grigoriadou; D Pytel; F Zhang; J Ye; C Koumenis; D Cavener; J A Diehl
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

10.  Cyclin D2 protein stability is regulated in pancreatic beta-cells.

Authors:  Lu Mei He; Daniel J Sartori; Monica Teta; Lynn M Opare-Addo; Matthew M Rankin; Simon Y Long; J Alan Diehl; Jake A Kushner
Journal:  Mol Endocrinol       Date:  2009-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.